<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bomfim TR</submitter><funding>NIA NIH HHS</funding><funding>CIHR</funding><pagination>1339-53</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3314445</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>122(4)</volume><pubmed_abstract>Defective brain insulin signaling has been suggested to contribute to the cognitive deficits in patients with Alzheimer's disease (AD). Although a connection between AD and diabetes has been suggested, a major unknown is the mechanism(s) by which insulin resistance in the brain arises in individuals with AD. Here, we show that serine phosphorylation of IRS-1 (IRS-1pSer) is common to both diseases. Brain tissue from humans with AD had elevated levels of IRS-1pSer and activated JNK, analogous to what occurs in peripheral tissue in patients with diabetes. We found that amyloid-β peptide (Aβ) oligomers, synaptotoxins that accumulate in the brains of AD patients, activated the JNK/TNF-α pathway, induced IRS-1 phosphorylation at multiple serine residues, and inhibited physiological IRS-1pTyr in </pubmed_abstract><journal>The Journal of clinical investigation</journal><pubmed_title>An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.</pubmed_title><pmcid>PMC3314445</pmcid><funding_grant_id>90396</funding_grant_id><funding_grant_id>R01-AG22547</funding_grant_id><funding_grant_id>R01 AG018877</funding_grant_id><funding_grant_id>MOP-77734</funding_grant_id><funding_grant_id>R01 AG022547</funding_grant_id><funding_grant_id>R01-AG18877</funding_grant_id><pubmed_authors>Klein WL</pubmed_authors><pubmed_authors>Bomfim TR</pubmed_authors><pubmed_authors>Sathler LB</pubmed_authors><pubmed_authors>Kazi H</pubmed_authors><pubmed_authors>Forny-Germano L</pubmed_authors><pubmed_authors>Munoz DP</pubmed_authors><pubmed_authors>McClean PL</pubmed_authors><pubmed_authors>Brito-Moreira J</pubmed_authors><pubmed_authors>Houzel JC</pubmed_authors><pubmed_authors>Talbot K</pubmed_authors><pubmed_authors>De Felice FG</pubmed_authors><pubmed_authors>Silverman MA</pubmed_authors><pubmed_authors>Melo HM</pubmed_authors><pubmed_authors>Arnold SE</pubmed_authors><pubmed_authors>Decker H</pubmed_authors><pubmed_authors>Ferreira ST</pubmed_authors><pubmed_authors>Holscher C</pubmed_authors></additional><is_claimable>false</is_claimable><name>An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.</name><description>Defective brain insulin signaling has been suggested to contribute to the cognitive deficits in patients with Alzheimer's disease (AD). Although a connection between AD and diabetes has been suggested, a major unknown is the mechanism(s) by which insulin resistance in the brain arises in individuals with AD. Here, we show that serine phosphorylation of IRS-1 (IRS-1pSer) is common to both diseases. Brain tissue from humans with AD had elevated levels of IRS-1pSer and activated JNK, analogous to what occurs in peripheral tissue in patients with diabetes. We found that amyloid-β peptide (Aβ) oligomers, synaptotoxins that accumulate in the brains of AD patients, activated the JNK/TNF-α pathway, induced IRS-1 phosphorylation at multiple serine residues, and inhibited physiological IRS-1pTyr in </description><dates><release>2012-01-01T00:00:00Z</release><publication>2012 Apr</publication><modification>2025-04-05T15:41:59.346Z</modification><creation>2019-03-27T00:51:40Z</creation></dates><accession>S-EPMC3314445</accession><cross_references><pubmed>22476196</pubmed><doi>10.1172/jci57256</doi><doi>10.1172/JCI57256</doi></cross_references></HashMap>